Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia

Executive Summary

ARIBIO CEO tells Scrip how the South Korean biotech is aiming to develop a multi-modal drug for both Alzheimer’s disease and vascular dementia using its innovative platform technology, which can cut development periods and costs and better predict clinical trial success.

You may also be interested in...



BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel